Anavex life sciences announces exceeding of enrollment target for the anavex®2-73 (blarcamesine) excellence phase 2/3 rett syndrome clinical trial

New york, feb. 02, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced the total enrollment of 92 patients with rett syndrome for the anavex®2-73 (blarcamesine) excellence phase 2/3 study in rett syndrome patients ages ≥ 5 years to 17 (inclusive). this exceeds the original enrollment target and the company expects to announce topline results from this study in 2h 2023.
AVXL Ratings Summary
AVXL Quant Ranking